IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer

Timothy A Yap; Alberto Bessudo; Erika Hamilton; Jasgit Sachdev; Manish R Patel; Jordi Rodon; Lena Evilevitch; Meghan Duncan; Wei Guo; Sujatha Kumar; Sharon Lu; Bruce J Dezube; Nashat Gabrail

doi:10.1136/jitc-2021-003924

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Alerts

PDF

PDF +
Supplementary
Material

Clinical/translational cancer immunotherapy

Original research

IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer

Log in using your username and password

Main menu

Log in using your username and password

You are here

Read the full text or download the PDF:

Log in using your username and password